ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Sep 2020
Last Updated on 01 Sep 2020
A- A+
Guidance Recommendations
The MOH Drug Advisory Committee has recommended to:
  • Reclassify mycophenolate mofetil 250 mg capsule and 500 mg tablet from the Medication Assistance Fund (MAF) to the MOH Standard Drug List (SDL); and
  • List mycophenolate mofetil 500 mg powder for solution for infusion on the SDL
in view of favourable cost effectiveness compared to other immunosuppressants at the prices proposed by the manufacturer.

Subsidy status
SDL subsidy will apply for induction and maintenance treatment of active lupus nephritis and for all registered indications of mycophenolate mofetil in Singapore:
  • Prophylaxis of acute organ rejection and treatment of refractory organ rejection in patients receiving allogeneic renal transplants,
  • Prophylaxis of acute organ rejection and increased graft and patient survival in patients receiving allogeneic cardiac transplants, and
  • Prophylaxis of acute organ rejection in patients receiving allogeneic hepatic transplants.

Previous versions of the guidance may be found here
Mycophenolate mofetil for immunosuppression (1 Sept 2020)